Stockreport

Ultragenyx Announces Positive 24-week Data from First Cohort of Phase 1/2 Study of DTX401 Gene Therapy in Glycogen Storage Disease Type Ia

Ultragenyx Pharmaceutical Inc.  (RARE) 
Last ultragenyx pharmaceutical inc. earnings: 2/13 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.ultragenyx.com/investor-relations
PDF DTX401 Response in Time to Hypoglycemia and Improved Glucose Control Maintained or Improved in All Three Patients Data from Higher-dose Cohort 2 Expected Mid-2019 NOV [Read more]